Farther Finance Advisors LLC Lowers Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Farther Finance Advisors LLC decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 52.8% in the 4th quarter, HoldingsChannel reports. The firm owned 764 shares of the biopharmaceutical company’s stock after selling 856 shares during the quarter. Farther Finance Advisors LLC’s holdings in Halozyme Therapeutics were worth $37,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Wealthfront Advisers LLC purchased a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $2,096,000. Future Fund LLC lifted its stake in Halozyme Therapeutics by 58.6% in the fourth quarter. Future Fund LLC now owns 17,596 shares of the biopharmaceutical company’s stock worth $841,000 after acquiring an additional 6,500 shares during the last quarter. Isthmus Partners LLC purchased a new position in Halozyme Therapeutics in the fourth quarter worth approximately $321,000. Oak Hill Wealth Advisors LLC lifted its stake in Halozyme Therapeutics by 200.0% in the fourth quarter. Oak Hill Wealth Advisors LLC now owns 10,800 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 21,600 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. lifted its stake in Halozyme Therapeutics by 129.3% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 19,494 shares of the biopharmaceutical company’s stock worth $932,000 after acquiring an additional 10,994 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 31,697 shares of company stock worth $1,754,451. Corporate insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of recent research reports. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Wells Fargo & Company cut their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Benchmark reissued a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $65.16 on Monday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock has a market capitalization of $8.05 billion, a P/E ratio of 19.00, a P/E/G ratio of 0.42 and a beta of 1.32. The company’s fifty day moving average is $58.20 and its two-hundred day moving average is $54.66. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.